{"id":"nct:NCT03705234","kind":"trial","title":"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease","authors":["University of Oxford"],"author_count":1,"year":2018,"published":"2018-10-15","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03705234","source_url":"https://clinicaltrials.gov/study/NCT03705234","archive_url":"https://space-kitty.com/papers/nct:NCT03705234","updated":"2026-05-01","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU\\_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to treat blocked arteries.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease"],"details":{"acronym":"ORION-4","status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":16124,"sponsor":"University of Oxford","conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: Inclisiran","DRUG: Placebo"],"start_date":"2018-10-30","start_date_type":"ACTUAL","primary_completion_date":"2026-10-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}